Clinical trial

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

NCT00126672

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-12-20

PhasePHASE2

Study timeline

Study start (actual)2005-12-20Date precision: day

Registry last updated2022-04-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Nonmalignant Neoplasmunresolved

Tuberous Sclerosisunresolved

Lymphangioleimyomatosisunresolved

Kidney Angiomyolipomaunresolved

Interventions

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

National Cancer Institute (NCI)collaborator

Wyeth is now a wholly owned subsidiary of Pfizercollaborator

Tuberous Sclerosis Alliancecollaborator

Mapped research locations

New YorkNew York, United States1 BostonMassachusetts, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 CincinnatiOhio, United States1 HartfordConnecticut, United States1 Loma LindaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00126672 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.